SlideShare a Scribd company logo
1 of 31
Download to read offline
DRUG PRICE CONTROL ORDER ACT,
1995
1
CONTENT
 INTRODUCTION
 HISTORY
 AMMENDMENTS
 OBJECTIVES
 DEFINITIONS
 PRICES OF BULK DRUGS
 INFORMATION REQUIRED FROM
MANUFACTURER TO THE GOVERNMENT
 RETAIL PRICE OF FORMULATION
 POWERS TO FIX PRICE OF SCHEDULED
FORMULATION 2
Cont…….
 FIXATION OF PRICE UNDER CERTAIN
CIRCUMSTANCES
 POWER TO RECOVER OVERCHARGED AMOUNT
 CONTROL OF SALE PRICES OF BULK DRUG AND
FORMULATION
 SALE OF SPLIT QUANTITY OF FORMULATION.
 SCHEDULES RELATED WITH DPCO ACT, 1995.
 OFFENCES AND PENALTIES.
 REFERENCES.
3
INTRODUCTION
DPCO ACT, 1995
CONFIRMED BY SECTION 3 OF
ESSENTIAL COMMODITIES ACT, 1955.
4
HISTORY
IN 1966, PARLIAMENT MEMBERS FELT THAT
MANUFACTURERS CHARGING HIGH RATE ON
DRUGS.
TO CONTROL ON HIGH DRUG RATES,
DPCO ACT 1966 WAS PASSED UNDER SECTION 3 OF
ESSENTIAL COMMODITIES ACT 1955.
5
DPCO ACT, 1966 REPLACED BY DPCO ACT, 1970.
IN 1974, HATHI COMMITTEE WAS FORMED AND
SUBMITTED IT’S REPORTS IN 1975.
DPCO ACT, 1970 REPLACED BY DPCO ACT, 1987.
FINALLY DPCO ACT, 1987 REPLACED BY DPCO ACT,
1995. 6
7
AMMENDMENTS
 DRUG PRICE CONTROL ORDER, 1970
 DRUG PRICE CONTROL ORDER, 1979
 DRUG PRICE CONTROL ORDER, 1987
 DRUG PRICE CONTROL ORDER, 1991
 DRUG PRICE CONTROL ORDER, 1995
8
OBJECTIVES
 TO ACHEIVE ADEQUATE PRODUCTION
 TO REGULATE EQUAL DISTRIBUTION
 TO MAINTAIN AND INCREASE SUPPLY OF BULK
DRUGS
 TO MAKE AT FAIR PRICES.
9
DEFINITIONS
BULK DRUGS :-
IT MEANS ANY PHARMACEUTICAL,
CHEMICAL AND BIOLOGICAL OR PLANT
PRODUCT CONFORM TO PHARMACOPOEIAL
STANDARDS SPECIFIED IN D AND C ACT, 1940.
CEILING PRICE:-
PRICE FIXED BY GOVERNMENT FOR SCHEDULED
FORMULATION.
DRUG :-
SUBSTANCE INTENDED TO BE USED FOR OR IN
THE DIAGNOSIS,TREATMENT, OR PREVENTION
OF ANY DISEASE OR DISORDER IN HUMAN OR
ANIMAL.
RETAIL PRICE :-
RETAIL PRICE OF DRUG FIXED IN ACCORDANCE
WITH PROVISIONS OF DPCO 1995 AND INCLUDE
CEILING PRICE.
SCHEDULED BULK DRUG :-
IT MEANS BULK DRUG SPECIFIED IN FIRST
SCHEDULE. 10
PRICES OF BULK DRUGS
 GOVERNMENT HAS POWER TO FIX THE
MAXIMUM SALE PRICE.
A. WHILE FIXING THE SALE PRICE GOVERNMENT
SHALL TAKE INTO FOLLOWING
CONSIDERATIONS:-
 POST-TAX RETURN OF 14% ON NET WORTH.
 RETURN OF 22% ON CAPITAL EMPLOYED.
11
 FOR NEW PLANT, RETURN OF 12% BASED ON
LONG TERM MARGINAL COST.
 ON THE BASIC STAGE OF PRODUCTION, POST TAX
RETURN OF 18% ON NET WORTH OR 26% ON
CAPITAL EMPLOYED.
12
 AT THE TIME OF PRODUCTION OF DRUG,
MANUFACTURER FILL DETAIL IN FORM-1 AND
GIVE NECESSARY INFORMATION TO
GOVERNMENT WITHIN 15 DAYS.
 MAKE NECESSARY INQUIRY AND THEN
GOVERNMENT FIX MAXIMUM SALE PRICE IF
BULK DRUG AND NOTED IN OFFICIAL GAZETTE.
 GOVR. ALSO FIX OR REVISE THE PRICE OF NON-
SCHEDULED BULK DRUGS.
13
14
INFORMATION REQUIRED FROM
MANUFACTURER TO THE
GOVERNMENT
 FOR THE BOTH SCHEDULED AND NON-
SCHEDULED BULK DRUGS
 LIST OF DRUG PRODUCED WITH COST IN FORM 1
AND 2 RESP.
 BUT FOR SCHEDULED BULK DRUGS IT SHOULD
GIVEN BY 30 SEPTEMBER EVERY YEAR.
RETAIL PRICE OF FORMULATION
CALCULATION :-
FORMULA :
R.P. = ( M.C.+C.C.+P.M.+P.C. ) * ( 1+ MAPE / 100 ) + ED.
WHERE, R.P. = RETAIL PRICE
M.C.= MATERIAL COST
C.C.= CONVERSION COST
P.M.= PACKAGING MATERIAL COST
P.C.= PACKING CHARGES
15
MAPE= MAXIMUM ALLOWABLE POST
MANUFACTURING EXPENSES
ED = EXCISE DUTY
16
17
POWER TO FIX RETAIL PRICE OF
SCHEDULED FORMULATION
 GOVERNMENT FIX THE RETAIL PRICE OF BULK
DRUG.
 AND MANUFACTURER USE DRUGS IN
SCHEDULED FORMULATION.
 FOR PRICE REVISION OF SUCH FORMULATION
MANUFACTURER SHOULD APPLY WITHIN 30
DAYS.
 FROM DATE OF RECEIPT OF COMPLETE
INFORMATION GOVR. FIX RETAIL PRICE WITHIN 2
MONTHS.
WITHOUT APPROVAL OF GOVERNMENT,
MANUFACTURER SHOULD NOT INCREASE
RETAIL PRICE OF DRUG.
MANUFACTURER SHOULD NOT MARKETED NEW
FORMULATION.
NO PERSON SHALL SELL IMPORTED SCHEDULED
FORMULATION. 18
POWER TO FIX CEILING PRICE OF
SCHEDULED FORMULATION
 GOVERNMENT FIX THE CEILING PRICE OF
SCHEDULED FORMULATION WITH FORMULA
GIVEN IN THE PARAGRAPH 7 KEEP COST AND
EFFICIENCY OR BOTH.
 CEILING PRICE FOR FORMULATION INCLUDING
THOSE SOLD UNDER GENERIC NAME.
 FIXED REVISED CEILING PRICE FOR SCHEDULE
FORMULATION EITHER ON IT’S OWN MOTION OR
ON APPLICATION MADE IN PRESCRIBED FORM.
19
POWER TO REVISE PRICE OF BULK
DRUG AND FORMULATION
 GOVERNMENT FIX OR REVISE RETAIL PRICE OF
ONE OR MORE FORMULATION.
 AS THE PRE-TAX RETURN ON SALES TURNOVER
OF FORMULATION THEN THE SCCHEDULED AND
NON-SCHEDULED FORMULATION.
20
FIXATION OF PRICE UNDER CERTAIN
CIRCUMSTANCES
 IF ANY MANUFACTURER OF BULK DRUG FAILS
TO SUBMIT THE APPLICATION FOR FIXATION OR
REVISION OF PRICE OR FAILS TO GIVE
INFORMATION WITHIN SPECIFIED TIME PERIOD.
 THEN GOVERNMENT FIX PRICE OF THE BULK
DRUG.
21
POWER TO RECOVER OVERCHARGED
AMOUNT
 IF ANY MANUFACTURER OR IMPORTER
CHARGING HIGHER PRICE THAN THE PRICE
FIXED BY GOVERNMENT
 THEN GOVERNMENT MAY RECOVER THE
OVERCHARGED AMOUNT.
22
CONTROL OF SALE PRICES OF BULK
DRUG AND FORMULATION
 NO PERSON OR RETAILER SHALL SALE THE
DRUG/ FORMULATION
 TO ANY CUSTOMER AT INCREASING PRICE
SPECIFIED IN CURRENT PRICE LIST INDICATED
ON CONTAINER LABEL.
23
SALE OF SPLIT QUANTITY OF
FORMULATION
 NO DEALER SHALL SELL THE LOOSE QUANTITY
OF FORMULATION
 AT PRICE EXCEEDING PRO-RATA PRICES OF
FORMULATION PLUS 5%.
24
SCHEDULES RELATED WITH DPCO
ACT, 1995
FIRST SCHEDULE
 FIRST SCHEDULE INCLUDES 76 BULK DRUGS.
 Eg. PENICILLIN, RANITIDINE, CHLOROQUINE ETC.
25
SECOND SCHEDULE
 DIFFERENT FORMS INCLUDED :-
 FORM- 1 :- APPLICATION FOR FIXATION/
REVISION OF PRICE.
 FORM- 2 :- INFORMATION RELATED WITH PRICE
OF NON-SCHEDULED BULK DRUG.
 FORM-3 :- APPLICATION FOR
APPROVAL/REVISION OF PRICE OF SCHEDULED
FORMULATION. 26
 FORM-4 :- APPLICATION FOR
APPROVAL/REVISION OF PRICE OF SCHEDULED
FORMULATION IMPORTED IN FINISHED FORM.
 FORM-5 :- FORM OF PRICE LIST
 FORM- 6 :- YEARLY INFORMATION ON TURNOVER
AND ALLOCATION OF SALES AND EXPENCES.
27
THIRD SCHEDULE
INCLUDE,
CATEGORY A :- LARGE UNIT WITH TURNOVER
EXCEEDING Rs. 6 CRORES PER ANNUM.
CATEGORY B :- MEDIUM SIZED UNIT TURNOVER
BETWEEN Rs. 1 CRORE TO 6 CRORE PER ANNUM.
CATEGORY C :- OTHER UNITS WITH TURNOVER OF
LESS THAN Rs. 1 CRORE PER ANNUM.
28
OFFENCES AND PENALTIES
PENALTIES—
 HE SHALL BE PUNISHABLE WITH IMPRISONMENT
FOR ONE YEAR AND ALSO LIABLE TO FINE.
 IN THE CASE OF ANY OTHER ORDER, WITH
IMPRISONMENT FOR NOT LESS THAN THREE
MONTHS BUT WHICH MAY EXTEND TO SEVEN
YEARS AND ALSO BE LIABLE TO FINE.
29
REFERENCES
 DR. KUCHEKAR B.S., KHADATARE A.M., ITKAR
S.C., “FORENSIC PHARMACY”, ED. 7th
, 2008, NIRALI
PRAKASHAN, P. 3.1-3.29.
 SAMPATH K. “ PHARMACEUTICAL
JURISPRUDENCE”, ED. 3rd
, BIRLA PUBLICATION, P.
170-177.
 GANDHI NEERJA, POPLI HARVINDER,
“PHARMACEUTICAL JURISPRUDENCE”, ED.1st
,
2010, CBS PUBLICATION, P. 136-154.
30
31

More Related Content

What's hot

Labeling in india
Labeling in indiaLabeling in india
Labeling in indiabdvfgbdhg
 
Drug and price controle order
Drug and price controle orderDrug and price controle order
Drug and price controle orderShubham Sharma
 
Drugs and magic remedies act
Drugs and magic remedies actDrugs and magic remedies act
Drugs and magic remedies actAmit Satpute
 
Manufacture of drugs (other than homeopathy)
Manufacture of drugs (other than homeopathy)Manufacture of drugs (other than homeopathy)
Manufacture of drugs (other than homeopathy)Robin Gulati
 
Drugs & Cosmetics Act 1940 part III
Drugs & Cosmetics Act 1940 part IIIDrugs & Cosmetics Act 1940 part III
Drugs & Cosmetics Act 1940 part IIIPranay Sethiya
 
Drugs & magic remedies act 1954 & rules 1955
Drugs & magic remedies act 1954 & rules 1955Drugs & magic remedies act 1954 & rules 1955
Drugs & magic remedies act 1954 & rules 1955Ravikumar Patil
 
Drug technical advisory board (dtab)
Drug technical advisory board (dtab)Drug technical advisory board (dtab)
Drug technical advisory board (dtab)MukulArora44
 
Over the counter (OTC) sales
Over the counter (OTC) salesOver the counter (OTC) sales
Over the counter (OTC) salessunayanamali
 
Codes of pharmaceutical ethics
Codes of pharmaceutical ethicsCodes of pharmaceutical ethics
Codes of pharmaceutical ethicsAshish Chaudhari
 
Pharmaceutical Legislations Notes (Pharmaceutical Jurisprudence Ist)
Pharmaceutical Legislations Notes (Pharmaceutical Jurisprudence Ist)Pharmaceutical Legislations Notes (Pharmaceutical Jurisprudence Ist)
Pharmaceutical Legislations Notes (Pharmaceutical Jurisprudence Ist)RAHUL PAL
 
National pharmaceutical pricing authority
National pharmaceutical pricing authority National pharmaceutical pricing authority
National pharmaceutical pricing authority TiyaPatel2
 
Pharmaceutical legislation
Pharmaceutical legislationPharmaceutical legislation
Pharmaceutical legislationChandrika Mourya
 
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )JAYACHANDRA AKUTHOTA
 
Drugs & Cosmetics Act 1940 Part VIII
Drugs & Cosmetics Act 1940 Part VIIIDrugs & Cosmetics Act 1940 Part VIII
Drugs & Cosmetics Act 1940 Part VIIIPranay Sethiya
 
Pharaceutical Legislation
Pharaceutical LegislationPharaceutical Legislation
Pharaceutical LegislationRupali Bhoje
 
The prevention of cruelty to animals act 1960
The prevention of cruelty to animals act 1960The prevention of cruelty to animals act 1960
The prevention of cruelty to animals act 1960Shaik Rasheed
 
Drugs and magic remedies act 1954 and rules
Drugs and magic remedies act 1954 and rules   Drugs and magic remedies act 1954 and rules
Drugs and magic remedies act 1954 and rules Rupali Bhoje
 

What's hot (20)

Labeling in india
Labeling in indiaLabeling in india
Labeling in india
 
Drug and price controle order
Drug and price controle orderDrug and price controle order
Drug and price controle order
 
Drugs and magic remedies act
Drugs and magic remedies actDrugs and magic remedies act
Drugs and magic remedies act
 
Manufacture of drugs (other than homeopathy)
Manufacture of drugs (other than homeopathy)Manufacture of drugs (other than homeopathy)
Manufacture of drugs (other than homeopathy)
 
Drugs & Cosmetics Act 1940 part III
Drugs & Cosmetics Act 1940 part IIIDrugs & Cosmetics Act 1940 part III
Drugs & Cosmetics Act 1940 part III
 
Drugs & magic remedies act 1954 & rules 1955
Drugs & magic remedies act 1954 & rules 1955Drugs & magic remedies act 1954 & rules 1955
Drugs & magic remedies act 1954 & rules 1955
 
The pharmacy act
The pharmacy actThe pharmacy act
The pharmacy act
 
Drug technical advisory board (dtab)
Drug technical advisory board (dtab)Drug technical advisory board (dtab)
Drug technical advisory board (dtab)
 
Over the counter (OTC) sales
Over the counter (OTC) salesOver the counter (OTC) sales
Over the counter (OTC) sales
 
Pharmacy Act 1948
Pharmacy Act 1948Pharmacy Act 1948
Pharmacy Act 1948
 
Codes of pharmaceutical ethics
Codes of pharmaceutical ethicsCodes of pharmaceutical ethics
Codes of pharmaceutical ethics
 
Nppa
NppaNppa
Nppa
 
Pharmaceutical Legislations Notes (Pharmaceutical Jurisprudence Ist)
Pharmaceutical Legislations Notes (Pharmaceutical Jurisprudence Ist)Pharmaceutical Legislations Notes (Pharmaceutical Jurisprudence Ist)
Pharmaceutical Legislations Notes (Pharmaceutical Jurisprudence Ist)
 
National pharmaceutical pricing authority
National pharmaceutical pricing authority National pharmaceutical pricing authority
National pharmaceutical pricing authority
 
Pharmaceutical legislation
Pharmaceutical legislationPharmaceutical legislation
Pharmaceutical legislation
 
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
 
Drugs & Cosmetics Act 1940 Part VIII
Drugs & Cosmetics Act 1940 Part VIIIDrugs & Cosmetics Act 1940 Part VIII
Drugs & Cosmetics Act 1940 Part VIII
 
Pharaceutical Legislation
Pharaceutical LegislationPharaceutical Legislation
Pharaceutical Legislation
 
The prevention of cruelty to animals act 1960
The prevention of cruelty to animals act 1960The prevention of cruelty to animals act 1960
The prevention of cruelty to animals act 1960
 
Drugs and magic remedies act 1954 and rules
Drugs and magic remedies act 1954 and rules   Drugs and magic remedies act 1954 and rules
Drugs and magic remedies act 1954 and rules
 

Similar to 5 dpco 1995

National pharmaceutical pricing authority with drugs price control order (dpc...
National pharmaceutical pricing authority with drugs price control order (dpc...National pharmaceutical pricing authority with drugs price control order (dpc...
National pharmaceutical pricing authority with drugs price control order (dpc...Tushar Morankar
 
NATIONAL PHARMACEUTICAL PRICING AUTHORITY.pptx
NATIONAL PHARMACEUTICAL PRICING AUTHORITY.pptxNATIONAL PHARMACEUTICAL PRICING AUTHORITY.pptx
NATIONAL PHARMACEUTICAL PRICING AUTHORITY.pptxJagat Pal Yadav
 
drugpricecontrolorder.pptx
drugpricecontrolorder.pptxdrugpricecontrolorder.pptx
drugpricecontrolorder.pptxIfraAzhar
 
The drugs (prices control) order,
The drugs (prices control) order,The drugs (prices control) order,
The drugs (prices control) order,Sharon Vijayanand
 
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015 Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015 Anup Soans
 
Drug Price control order 2013
Drug Price control order 2013Drug Price control order 2013
Drug Price control order 2013Ramkrishna Bannai
 
NATIONAL PRICING AUTHORITY (1).ppt
NATIONAL PRICING AUTHORITY (1).pptNATIONAL PRICING AUTHORITY (1).ppt
NATIONAL PRICING AUTHORITY (1).pptDinesh150434
 
Drug Price Control Order 2013
Drug Price Control Order 2013Drug Price Control Order 2013
Drug Price Control Order 2013Gaurav Andhansare
 
wwwww9. Drug Price control Order & National Drug Policy (2).pdf
wwwww9. Drug Price control Order & National Drug Policy (2).pdfwwwww9. Drug Price control Order & National Drug Policy (2).pdf
wwwww9. Drug Price control Order & National Drug Policy (2).pdfkusumAkki1
 
Distribution Setup.pdf
Distribution Setup.pdfDistribution Setup.pdf
Distribution Setup.pdfEasyTechHome
 
Documentation In Pharmaceutical Industry(Master Formula Record,DMF,Distributi...
Documentation In Pharmaceutical Industry(Master Formula Record,DMF,Distributi...Documentation In Pharmaceutical Industry(Master Formula Record,DMF,Distributi...
Documentation In Pharmaceutical Industry(Master Formula Record,DMF,Distributi...RUSHIKESHSHINDE80
 
DRUG PRICE CONTROLE ORDER OR NATIONAL PHARMACEUTICAL PRICING AUTHORITY
DRUG PRICE CONTROLE ORDER OR NATIONAL PHARMACEUTICAL PRICING AUTHORITYDRUG PRICE CONTROLE ORDER OR NATIONAL PHARMACEUTICAL PRICING AUTHORITY
DRUG PRICE CONTROLE ORDER OR NATIONAL PHARMACEUTICAL PRICING AUTHORITYGAMPA kumar
 

Similar to 5 dpco 1995 (20)

DPCO.pptx
DPCO.pptxDPCO.pptx
DPCO.pptx
 
National pharmaceutical pricing authority with drugs price control order (dpc...
National pharmaceutical pricing authority with drugs price control order (dpc...National pharmaceutical pricing authority with drugs price control order (dpc...
National pharmaceutical pricing authority with drugs price control order (dpc...
 
NATIONAL PHARMACEUTICAL PRICING AUTHORITY.pptx
NATIONAL PHARMACEUTICAL PRICING AUTHORITY.pptxNATIONAL PHARMACEUTICAL PRICING AUTHORITY.pptx
NATIONAL PHARMACEUTICAL PRICING AUTHORITY.pptx
 
drugpricecontrolorder.pptx
drugpricecontrolorder.pptxdrugpricecontrolorder.pptx
drugpricecontrolorder.pptx
 
Drug pricing policy india
Drug pricing policy indiaDrug pricing policy india
Drug pricing policy india
 
Dpco as per pci
Dpco as per pciDpco as per pci
Dpco as per pci
 
Legal requirements
Legal requirementsLegal requirements
Legal requirements
 
The drugs (prices control) order,
The drugs (prices control) order,The drugs (prices control) order,
The drugs (prices control) order,
 
NPPA-WPS Office.pptx
NPPA-WPS Office.pptxNPPA-WPS Office.pptx
NPPA-WPS Office.pptx
 
Ska
SkaSka
Ska
 
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015 Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
Compendium of Notified Ceiling Prices of Scheduled Drugs - 2015
 
Drug Price control order 2013
Drug Price control order 2013Drug Price control order 2013
Drug Price control order 2013
 
NATIONAL PRICING AUTHORITY (1).ppt
NATIONAL PRICING AUTHORITY (1).pptNATIONAL PRICING AUTHORITY (1).ppt
NATIONAL PRICING AUTHORITY (1).ppt
 
Drug Price Control Order 2013
Drug Price Control Order 2013Drug Price Control Order 2013
Drug Price Control Order 2013
 
wwwww9. Drug Price control Order & National Drug Policy (2).pdf
wwwww9. Drug Price control Order & National Drug Policy (2).pdfwwwww9. Drug Price control Order & National Drug Policy (2).pdf
wwwww9. Drug Price control Order & National Drug Policy (2).pdf
 
Distribution Setup.pdf
Distribution Setup.pdfDistribution Setup.pdf
Distribution Setup.pdf
 
New drug policy 1994
New drug policy 1994New drug policy 1994
New drug policy 1994
 
Documentation In Pharmaceutical Industry(Master Formula Record,DMF,Distributi...
Documentation In Pharmaceutical Industry(Master Formula Record,DMF,Distributi...Documentation In Pharmaceutical Industry(Master Formula Record,DMF,Distributi...
Documentation In Pharmaceutical Industry(Master Formula Record,DMF,Distributi...
 
DRUG PRICE CONTROLE ORDER OR NATIONAL PHARMACEUTICAL PRICING AUTHORITY
DRUG PRICE CONTROLE ORDER OR NATIONAL PHARMACEUTICAL PRICING AUTHORITYDRUG PRICE CONTROLE ORDER OR NATIONAL PHARMACEUTICAL PRICING AUTHORITY
DRUG PRICE CONTROLE ORDER OR NATIONAL PHARMACEUTICAL PRICING AUTHORITY
 
License.ppt
License.pptLicense.ppt
License.ppt
 

Recently uploaded

PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxAbhishek943418
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Musculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxMusculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxraviapr7
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
ANEMIA IN PREGNANCY by Dr. Akebom Kidanemariam
ANEMIA IN PREGNANCY by Dr. Akebom KidanemariamANEMIA IN PREGNANCY by Dr. Akebom Kidanemariam
ANEMIA IN PREGNANCY by Dr. Akebom KidanemariamAkebom Gebremichael
 
Hypersensitivity and its classification .pptx
Hypersensitivity and its classification .pptxHypersensitivity and its classification .pptx
Hypersensitivity and its classification .pptxAkshay Shetty
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfDivya Kanojiya
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfMyThaoAiDoan
 

Recently uploaded (20)

PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptx
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Musculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxMusculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptx
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
ANEMIA IN PREGNANCY by Dr. Akebom Kidanemariam
ANEMIA IN PREGNANCY by Dr. Akebom KidanemariamANEMIA IN PREGNANCY by Dr. Akebom Kidanemariam
ANEMIA IN PREGNANCY by Dr. Akebom Kidanemariam
 
Hypersensitivity and its classification .pptx
Hypersensitivity and its classification .pptxHypersensitivity and its classification .pptx
Hypersensitivity and its classification .pptx
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdf
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
 

5 dpco 1995

  • 1. DRUG PRICE CONTROL ORDER ACT, 1995 1
  • 2. CONTENT  INTRODUCTION  HISTORY  AMMENDMENTS  OBJECTIVES  DEFINITIONS  PRICES OF BULK DRUGS  INFORMATION REQUIRED FROM MANUFACTURER TO THE GOVERNMENT  RETAIL PRICE OF FORMULATION  POWERS TO FIX PRICE OF SCHEDULED FORMULATION 2
  • 3. Cont…….  FIXATION OF PRICE UNDER CERTAIN CIRCUMSTANCES  POWER TO RECOVER OVERCHARGED AMOUNT  CONTROL OF SALE PRICES OF BULK DRUG AND FORMULATION  SALE OF SPLIT QUANTITY OF FORMULATION.  SCHEDULES RELATED WITH DPCO ACT, 1995.  OFFENCES AND PENALTIES.  REFERENCES. 3
  • 4. INTRODUCTION DPCO ACT, 1995 CONFIRMED BY SECTION 3 OF ESSENTIAL COMMODITIES ACT, 1955. 4
  • 5. HISTORY IN 1966, PARLIAMENT MEMBERS FELT THAT MANUFACTURERS CHARGING HIGH RATE ON DRUGS. TO CONTROL ON HIGH DRUG RATES, DPCO ACT 1966 WAS PASSED UNDER SECTION 3 OF ESSENTIAL COMMODITIES ACT 1955. 5
  • 6. DPCO ACT, 1966 REPLACED BY DPCO ACT, 1970. IN 1974, HATHI COMMITTEE WAS FORMED AND SUBMITTED IT’S REPORTS IN 1975. DPCO ACT, 1970 REPLACED BY DPCO ACT, 1987. FINALLY DPCO ACT, 1987 REPLACED BY DPCO ACT, 1995. 6
  • 7. 7 AMMENDMENTS  DRUG PRICE CONTROL ORDER, 1970  DRUG PRICE CONTROL ORDER, 1979  DRUG PRICE CONTROL ORDER, 1987  DRUG PRICE CONTROL ORDER, 1991  DRUG PRICE CONTROL ORDER, 1995
  • 8. 8 OBJECTIVES  TO ACHEIVE ADEQUATE PRODUCTION  TO REGULATE EQUAL DISTRIBUTION  TO MAINTAIN AND INCREASE SUPPLY OF BULK DRUGS  TO MAKE AT FAIR PRICES.
  • 9. 9 DEFINITIONS BULK DRUGS :- IT MEANS ANY PHARMACEUTICAL, CHEMICAL AND BIOLOGICAL OR PLANT PRODUCT CONFORM TO PHARMACOPOEIAL STANDARDS SPECIFIED IN D AND C ACT, 1940. CEILING PRICE:- PRICE FIXED BY GOVERNMENT FOR SCHEDULED FORMULATION.
  • 10. DRUG :- SUBSTANCE INTENDED TO BE USED FOR OR IN THE DIAGNOSIS,TREATMENT, OR PREVENTION OF ANY DISEASE OR DISORDER IN HUMAN OR ANIMAL. RETAIL PRICE :- RETAIL PRICE OF DRUG FIXED IN ACCORDANCE WITH PROVISIONS OF DPCO 1995 AND INCLUDE CEILING PRICE. SCHEDULED BULK DRUG :- IT MEANS BULK DRUG SPECIFIED IN FIRST SCHEDULE. 10
  • 11. PRICES OF BULK DRUGS  GOVERNMENT HAS POWER TO FIX THE MAXIMUM SALE PRICE. A. WHILE FIXING THE SALE PRICE GOVERNMENT SHALL TAKE INTO FOLLOWING CONSIDERATIONS:-  POST-TAX RETURN OF 14% ON NET WORTH.  RETURN OF 22% ON CAPITAL EMPLOYED. 11
  • 12.  FOR NEW PLANT, RETURN OF 12% BASED ON LONG TERM MARGINAL COST.  ON THE BASIC STAGE OF PRODUCTION, POST TAX RETURN OF 18% ON NET WORTH OR 26% ON CAPITAL EMPLOYED. 12
  • 13.  AT THE TIME OF PRODUCTION OF DRUG, MANUFACTURER FILL DETAIL IN FORM-1 AND GIVE NECESSARY INFORMATION TO GOVERNMENT WITHIN 15 DAYS.  MAKE NECESSARY INQUIRY AND THEN GOVERNMENT FIX MAXIMUM SALE PRICE IF BULK DRUG AND NOTED IN OFFICIAL GAZETTE.  GOVR. ALSO FIX OR REVISE THE PRICE OF NON- SCHEDULED BULK DRUGS. 13
  • 14. 14 INFORMATION REQUIRED FROM MANUFACTURER TO THE GOVERNMENT  FOR THE BOTH SCHEDULED AND NON- SCHEDULED BULK DRUGS  LIST OF DRUG PRODUCED WITH COST IN FORM 1 AND 2 RESP.  BUT FOR SCHEDULED BULK DRUGS IT SHOULD GIVEN BY 30 SEPTEMBER EVERY YEAR.
  • 15. RETAIL PRICE OF FORMULATION CALCULATION :- FORMULA : R.P. = ( M.C.+C.C.+P.M.+P.C. ) * ( 1+ MAPE / 100 ) + ED. WHERE, R.P. = RETAIL PRICE M.C.= MATERIAL COST C.C.= CONVERSION COST P.M.= PACKAGING MATERIAL COST P.C.= PACKING CHARGES 15
  • 16. MAPE= MAXIMUM ALLOWABLE POST MANUFACTURING EXPENSES ED = EXCISE DUTY 16
  • 17. 17 POWER TO FIX RETAIL PRICE OF SCHEDULED FORMULATION  GOVERNMENT FIX THE RETAIL PRICE OF BULK DRUG.  AND MANUFACTURER USE DRUGS IN SCHEDULED FORMULATION.  FOR PRICE REVISION OF SUCH FORMULATION MANUFACTURER SHOULD APPLY WITHIN 30 DAYS.
  • 18.  FROM DATE OF RECEIPT OF COMPLETE INFORMATION GOVR. FIX RETAIL PRICE WITHIN 2 MONTHS. WITHOUT APPROVAL OF GOVERNMENT, MANUFACTURER SHOULD NOT INCREASE RETAIL PRICE OF DRUG. MANUFACTURER SHOULD NOT MARKETED NEW FORMULATION. NO PERSON SHALL SELL IMPORTED SCHEDULED FORMULATION. 18
  • 19. POWER TO FIX CEILING PRICE OF SCHEDULED FORMULATION  GOVERNMENT FIX THE CEILING PRICE OF SCHEDULED FORMULATION WITH FORMULA GIVEN IN THE PARAGRAPH 7 KEEP COST AND EFFICIENCY OR BOTH.  CEILING PRICE FOR FORMULATION INCLUDING THOSE SOLD UNDER GENERIC NAME.  FIXED REVISED CEILING PRICE FOR SCHEDULE FORMULATION EITHER ON IT’S OWN MOTION OR ON APPLICATION MADE IN PRESCRIBED FORM. 19
  • 20. POWER TO REVISE PRICE OF BULK DRUG AND FORMULATION  GOVERNMENT FIX OR REVISE RETAIL PRICE OF ONE OR MORE FORMULATION.  AS THE PRE-TAX RETURN ON SALES TURNOVER OF FORMULATION THEN THE SCCHEDULED AND NON-SCHEDULED FORMULATION. 20
  • 21. FIXATION OF PRICE UNDER CERTAIN CIRCUMSTANCES  IF ANY MANUFACTURER OF BULK DRUG FAILS TO SUBMIT THE APPLICATION FOR FIXATION OR REVISION OF PRICE OR FAILS TO GIVE INFORMATION WITHIN SPECIFIED TIME PERIOD.  THEN GOVERNMENT FIX PRICE OF THE BULK DRUG. 21
  • 22. POWER TO RECOVER OVERCHARGED AMOUNT  IF ANY MANUFACTURER OR IMPORTER CHARGING HIGHER PRICE THAN THE PRICE FIXED BY GOVERNMENT  THEN GOVERNMENT MAY RECOVER THE OVERCHARGED AMOUNT. 22
  • 23. CONTROL OF SALE PRICES OF BULK DRUG AND FORMULATION  NO PERSON OR RETAILER SHALL SALE THE DRUG/ FORMULATION  TO ANY CUSTOMER AT INCREASING PRICE SPECIFIED IN CURRENT PRICE LIST INDICATED ON CONTAINER LABEL. 23
  • 24. SALE OF SPLIT QUANTITY OF FORMULATION  NO DEALER SHALL SELL THE LOOSE QUANTITY OF FORMULATION  AT PRICE EXCEEDING PRO-RATA PRICES OF FORMULATION PLUS 5%. 24
  • 25. SCHEDULES RELATED WITH DPCO ACT, 1995 FIRST SCHEDULE  FIRST SCHEDULE INCLUDES 76 BULK DRUGS.  Eg. PENICILLIN, RANITIDINE, CHLOROQUINE ETC. 25
  • 26. SECOND SCHEDULE  DIFFERENT FORMS INCLUDED :-  FORM- 1 :- APPLICATION FOR FIXATION/ REVISION OF PRICE.  FORM- 2 :- INFORMATION RELATED WITH PRICE OF NON-SCHEDULED BULK DRUG.  FORM-3 :- APPLICATION FOR APPROVAL/REVISION OF PRICE OF SCHEDULED FORMULATION. 26
  • 27.  FORM-4 :- APPLICATION FOR APPROVAL/REVISION OF PRICE OF SCHEDULED FORMULATION IMPORTED IN FINISHED FORM.  FORM-5 :- FORM OF PRICE LIST  FORM- 6 :- YEARLY INFORMATION ON TURNOVER AND ALLOCATION OF SALES AND EXPENCES. 27
  • 28. THIRD SCHEDULE INCLUDE, CATEGORY A :- LARGE UNIT WITH TURNOVER EXCEEDING Rs. 6 CRORES PER ANNUM. CATEGORY B :- MEDIUM SIZED UNIT TURNOVER BETWEEN Rs. 1 CRORE TO 6 CRORE PER ANNUM. CATEGORY C :- OTHER UNITS WITH TURNOVER OF LESS THAN Rs. 1 CRORE PER ANNUM. 28
  • 29. OFFENCES AND PENALTIES PENALTIES—  HE SHALL BE PUNISHABLE WITH IMPRISONMENT FOR ONE YEAR AND ALSO LIABLE TO FINE.  IN THE CASE OF ANY OTHER ORDER, WITH IMPRISONMENT FOR NOT LESS THAN THREE MONTHS BUT WHICH MAY EXTEND TO SEVEN YEARS AND ALSO BE LIABLE TO FINE. 29
  • 30. REFERENCES  DR. KUCHEKAR B.S., KHADATARE A.M., ITKAR S.C., “FORENSIC PHARMACY”, ED. 7th , 2008, NIRALI PRAKASHAN, P. 3.1-3.29.  SAMPATH K. “ PHARMACEUTICAL JURISPRUDENCE”, ED. 3rd , BIRLA PUBLICATION, P. 170-177.  GANDHI NEERJA, POPLI HARVINDER, “PHARMACEUTICAL JURISPRUDENCE”, ED.1st , 2010, CBS PUBLICATION, P. 136-154. 30
  • 31. 31